Bio-Technology General Corp. said it received permission from the Australian government to market its Oxandrin for pediatric growth disorders.
The maker of genetically engineered health-care products said Australia is the first country to approve the drug, which carries the generic name oxandrolone, for such disorders.
The drug will be marketed by biopharmaceutical firm CSL Ltd. of Australia under the Lonavar trademark, Bio-Technology said.
Terms of the licencing agreement weren't disclosed.
